OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolu
perigon
Last updated: April 15, 2026
OSE Immunotherapeutics' Chief Scientific Officer, Aurore Morello, will present a novel therapeutic strategy targeting the FPR2 GPCR. This pioneering approach aims to address unmet medical needs by modulating the FPR2 receptor's activity. The presentation will cover the preclinical and clinical development status of OSE-202, the company's lead drug candidate for this indication.
- OSE Immunotherapeutics is advancing a first-in-class therapeutic strategy focused on the FPR2 G-protein–coupled receptor (GPCR).
- Aurore Morello, PhD, Chief Scientific Officer, will present these findings.
- The presentation will unveil a novel therapeutic strategy for targeting the FPR2 GPCR.
- OSE-202 is the company's lead drug candidate for this therapeutic strategy.
- The presentation will detail the preclinical and clinical development status of OSE-202.
- This strategy aims to address significant unmet medical needs.
- OSE Immunotherapeutics is focused on developing innovative immunotherapies.
- The FPR2 receptor plays a role in various biological processes.
- Targeting FPR2 offers a potential new avenue for therapeutic intervention.
- The company is committed to advancing its pipeline of novel treatments.
- Further details on the mechanism of action will be discussed.
- The presentation will highlight the potential benefits of this novel approach.
- The scientific community anticipates significant insights from this presentation.
